- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Central scotoma.
Displaying page 1 of 1.
EudraCT Number: 2012-004758-27 | Sponsor Protocol Number: V1 | Start Date*: 2013-01-30 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde | ||
Full Title: fMRI analysis of the visual cortex in neovascular age-related macular degeneration | ||
Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 7 tesla magnet... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004769-15 | Sponsor Protocol Number: V1.2 | Start Date*: 2013-12-13 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Augenheilkunde | ||
Full Title: fMRI analysis of the visual cortex in neovascular Age-related Macular Degeneration | ||
Medical condition: 20 patients with neovascular age-related macular degeneration will be examined before and after 3 monthly administered intravitreal ranibizumab injections according to the label with 3 tesla magnet... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002531-15 | Sponsor Protocol Number: 09/0959 | Start Date*: 2016-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UCL Comprehensive Clinical Trials Unit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002202-70 | Sponsor Protocol Number: | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein (UK-SH) | |||||||||||||
Full Title: A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (... | |||||||||||||
Medical condition: Retinal function in patients with wet age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000425-31 | Sponsor Protocol Number: MGT010 | Start Date*: 2018-08-30 | |||||||||||
Sponsor Name:MeiraGTx UK II Ltd | |||||||||||||
Full Title: Long term follow-up study of participants following an open label, multicentre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy o... | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002873-88 | Sponsor Protocol Number: MGT-RPGR-021 | Start Date*: 2022-07-19 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NL (Ongoing) BE (Completed) ES (Ongoing) FR (Completed) DK (Completed) DE (Prematurely Ended) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002255-37 | Sponsor Protocol Number: MGT-RPGR-022 | Start Date*: 2022-05-26 | |||||||||||
Sponsor Name:MeiraGTx UK II Limited | |||||||||||||
Full Title: Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene | |||||||||||||
Medical condition: X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) DK (Trial now transitioned) DE (Prematurely Ended) IT (Trial now transitioned) Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001405-90 | Sponsor Protocol Number: GS-LHON/CLIN/01 | Start Date*: 2013-12-26 | |||||||||||
Sponsor Name:GENSIGHT-BIOLOGICS | |||||||||||||
Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations... | |||||||||||||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005259-20 | Sponsor Protocol Number: OFT-ETAMSILATO-4.2.1 | Start Date*: 2015-02-13 | |||||||||||
Sponsor Name:Investigacion Independiente | |||||||||||||
Full Title: FASE IV-II CLINICAL TRIAL, PROOF OF CONCEPT, RANDOMIZED, SIMULATED CONTROLLED TREATMENT, DOUBLE BLINDED AND UNICENTRIC WITH TWO PARALLEL GROUPS, TO EVALUATE SAFETY AND EFFICACY OF INTRAVITREAL ADMI... | |||||||||||||
Medical condition: Aged related macula degeneration (ARMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001758-14 | Sponsor Protocol Number: 201677 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis | |||||||||||||
Medical condition: Giant Cell Arteritis (GCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
